Dr. Martens (LON:DOCS) Insider Acquires £151.11 in Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson bought 219 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The stock was acquired at an average price of GBX 69 per share, for a total transaction of £151.11.

Giles Wilson also recently made the following trade(s):

• On Tuesday, January 13th, Giles Wilson purchased 192 shares of Dr. Martens stock. The shares were acquired at an average price of GBX 78 per share, with a total value of £149.76.
• On Thursday, December 11th, Giles Wilson acquired 197 shares of Dr. Martens stock. The shares were bought at an average cost of GBX 76 per share, for a total transaction of £149.72.

Dr. Martens Stock Up 2.0%

DOCS opened at GBX 68.62 on Monday. The company has a market cap of £663.29 million, a P/E ratio of 40.37, a P/E/G ratio of 6.40 and a beta of 0.11. The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. Dr. Martens plc has a 12 month low of GBX 43.02 and a 12 month high of GBX 100.87. The business’s 50-day moving average price is GBX 73.90 and its 200-day moving average price is GBX 82.19.

Dr. Martens (LON:DOCS) last announced its earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, equities analysts expect that Dr. Martens plc will post 2.5809394 EPS for the current year.

Wall Street Analyst Weigh In

DOCS has been the subject of a number of research reports. Berenberg Bank reaffirmed a “buy” rating on shares of Dr. Martens in a report on Tuesday, January 27th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Dr. Martens in a research report on Tuesday, February 3rd. Finally, Peel Hunt reaffirmed a “buy” rating on shares of Dr. Martens in a report on Thursday, November 20th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Dr. Martens presently has an average rating of “Moderate Buy” and a consensus price target of GBX 6,000.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.